Open AccessPulmonary Sarcoidosis following Etanercept Treatment
Author(s) -
Kuljeet Bhamra,
Richard Stevens
Publication year - 2012
Publication title -
case reports in rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2090-6889
pISSN - 2090-6897
DOI - 10.1155/2012/724013
Subject(s) - etanercept , medicine , sarcoidosis , pulmonary sarcoidosis , dermatology , intensive care medicine , immunology , tumor necrosis factor alpha
Tumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like granulomatous disease developing after the initiation of anti-TNF- α therapy, with disease reversal after discontinuation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom